KLK1 is inhibited by several SMIs in the treatment of cardiovascular diseases 53, while the anti-CD14 antibody atibuclimab is administered to patients with amyotrophic lateral sclerosis 54. This evidence concerns the gene KLK1 and cardiovascular disorder.